C12N 2310/335
Modified t or u
Official title: Modified T or U
C12N2310/335 (Modified t or u) appears on 355 US grants and 578 published applications in this corpus.
Search patents in C12N- Granted patents
- 355
- Published applications
- 578
- Assignees
- 231
- Inventors
- 933
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 2 | 0 |
| 1995 | 0 | 0 |
| 1996 | 2 | 0 |
| 1997 | 12 | 0 |
| 1998 | 11 | 0 |
| 1999 | 13 | 0 |
| 2000 | 11 | 0 |
| 2001 | 9 | 2 |
| 2002 | 9 | 8 |
| 2003 | 5 | 20 |
| 2004 | 2 | 15 |
| 2005 | 2 | 11 |
| 2006 | 3 | 6 |
| 2007 | 2 | 5 |
| 2008 | 3 | 6 |
| 2009 | 4 | 9 |
| 2010 | 6 | 11 |
| 2011 | 4 | 11 |
| 2012 | 9 | 14 |
| 2013 | 9 | 21 |
| 2014 | 12 | 11 |
| 2015 | 16 | 34 |
| 2016 | 15 | 39 |
| 2017 | 12 | 25 |
| 2018 | 14 | 26 |
| 2019 | 28 | 32 |
| 2020 | 14 | 34 |
| 2021 | 27 | 35 |
| 2022 | 22 | 28 |
| 2023 | 15 | 35 |
| 2024 | 30 | 51 |
| 2025 | 27 | 54 |
| 2026 | 4 | 35 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Therapeutics for glycogen storage disease type iii11 Aug 2026US 12,703,858 B2Ultragenyx Pharmaceutical Inc.
- Muscle targeting complexes and formulations for treating myotonic dystrophy4 Aug 2026US 12,697,394 B2Dyne Therapeutics, Inc.
- Glypican-3-specific modified aptamer and use thereof30 Jun 2026US 12,668,803 B2Aptamer Sciences Inc.
- RNA preparations comprising purified modified RNA for reprogramming cells16 Jun 2026US 12,655,395 B2
- Antisense oligonucleotides directed to huntingtin30 Dec 2025US 12,509,681 B2
- Rna preparations comprising purified modified rna for reprogramming cells1 Oct 2026US 2026/0297538 A1The Trustees of the University of Pennsylvania
- Trem compositions and methods of use1 Oct 2026US 2026/0297575 A1Flagship Pioneering Innovations VI, LLC
- Modified iscb nucleases, modified guide rnas, and uses thereof24 Sep 2026US 2026/0286324 A1Aera Therapeutics, Inc.
- Antisense RNA (asRNA) Technology and Use Thereof24 Sep 2026US 2026/0286353 A11Globe Health Institute LLC
- RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of Use17 Sep 2026US 2026/0275351 A1Arrowhead Pharmaceuticals, Inc.
Most cited
By later US patents
- Inhibitors for replication of retroviruses and for the expression of oncogene products698US 5,264,423 AThe United States of America as represented by the Department of Health and Human Services · 1993
- Inhibitors for replication of retroviruses and for the expression of oncogene products619US 5,276,019 AThe United States of America as represented by the Department of Health and Human Services · 1994
- Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides619US 5,596,091 AThe Regents of the University of California · 1997
- Inhibitors for replication of retroviruses and for the expression of oncogene products567US 5,286,717 AThe United States of America as represented by the Department of Health and Human Services · 1994
- 2'deoxy-2'-alkylnucleotide containing nucleic acid521US 5,627,053 ARibozyme Pharmaceuticals, Inc. · 1997